Skip to main content
. Author manuscript; available in PMC: 2010 Aug 15.
Published in final edited form as: Cancer Res. 2009 Aug 4;69(16):6615–6623. doi: 10.1158/0008-5472.CAN-09-0685

Figure 1. Antitumor role of Fas ligand in vivo.

Figure 1

Tumor cells were injected in BALB/c WT, SCID, Pfp−/−, FasLgld/gld and Faslpr/lpr mice. (A) Survival of Renca-HA (1 × 104 subcutaneous) tumor-bearing SCID (n = 43), WT (n = 55), Pfp−/− (n = 45), FasLgld/gld (n = 54) and Faslpr/lpr (n = 51) mice. *P <0.0001 (WT compared to SCID; or Pfp−/− or Faslpr/lpr compared to FasLgld/gld) (two-sided log-rank test). (B) Lung metastases counts on day 14 following tumor (0.5 × 106 intravenous) injection. In some groups, mice were administered intraperitoneally with mAb MFL4 against Fas ligand or its isotype IgG (0.5 mg each) on day 0, 3, 7 and 10. *P < 0.0001 (ANOVA, two-sided) for WT (n = 23), Faslpr/lpr (n = 18) and Pfp−/− (n = 23) compared to SCID (n = 13) or FasLgld/gld (n = 18), or for MFL4-treated WT (n = 13), Pfp−/− (n = 13) or Faslpr/lpr (n = 8) compared to equal numbers of control isotype-treated mice. Data from 7 (A), and 6 (B) independent experiments.